1. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017
2. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial;Powles;Lancet,2018
3. National Comprehensive Cancer Network. Bladder Cancer (Version 6.2021). 2021. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417. Accessed: October 21, 2021.
4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016
5. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2021